APOA1 and coronary artery disorder: RVX-208 (RVX-000222) is a novel BET bromodomain antagonist and a small-molecule stimulator of apolipoprotein (Apo)-AI gene expression, developed by Resverlogix Corp (USA) for coronary artery disease (CAD) treatment [86].